Reovirus as a viable therapeutic option for the treatment of multiple myeloma

Clinical Cancer Research

Volumn 18, Issue 18, 2012, Pages 4962-4972

  Thirukkumaran, Chandini M ^a   Shi, Zhong Qiao ^a   Luider, Joanne ^b   Kopciuk, Karen ^a   Gao, He ^c   Bahlis, Nizar ^a   Neri, Paola ^a   Pho, Mark ^c   Stewart, Douglas ^a   Mansoor, Adnan ^b   Morris, Don G ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

^b CALGARY LABORATORY SERVICES   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC REOVIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW METASTASIS; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; EX VIVO STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; REOVIRUS; SINGLE DRUG DOSE; TUMOR VOLUME; VIRUS INACTIVATION;

ANIMALS; APOPTOSIS; AUTOPHAGY; BONE MARROW; CELL LINE, TUMOR; CYTOPATHOGENIC EFFECT, VIRAL; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; REOVIRIDAE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866411722     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3085     Document Type: Article

References (38)

1. Palumbo A, Attal M, Roussel M. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Clin Cancer Res 2011;17: 1253- 63.
2. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc 2010;85:225-30.
3. Ludwig H, Bolejack V, Crowley J, Blade J, Miguel JS, Kyle RA, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 2010;28:1599-605.
4. Anderson KC. The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 2012;30:445-52.
5. Kumar L, Verma R, Radhakrishnan VR. Recent advances in the management of multiple myeloma. Natl Med J India 2010;23:210-8.
6. Mitsiades CS, Davies FE, Laubach JP, Joshua D, San MJ, Anderson KC, et al. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol 2011;29:1916-23.
7. Tyler KL, Fielsd BN. Reoviruses. In:Fields BN,KnipeDM, editors. Fields virology. Philadelphia: Lippincott-Raven; 1996. p1597-623.
8. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998;17:3351-62.
9. Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 2004;101: 11099-104.
10. Thirukkumaran CM, Nodwell MJ, Hirasawa K, Shi ZQ, Diaz R, Luider J, et al. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res 2010;70:2435-44.
11. Steinbrunn T, Stühmer T, Gattenlöhner S, Rosenwald A, Mottok A, Unzicker C, et al. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood 2011;117: 1998-04.
12. Portier M, Moles JP, Mazars GR, Jeanteur P, Bataille R, Klein B, et al. p53 and RAS gene mutations in multiple myeloma. Oncogene 1992; 7:2539-43.
13. Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 1996;88:2699 -706.
14. Younes H, Leleu X, Hatjiharissi E, Moreau AS, Hideshima T, Richardson P, et al. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res 2007;13:3771-5.
15. Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 2010;9: 963- 75.
16. Bazzi M, Badros A. Multiple myeloma: implementing signalling pathways and molecular biology in clinical trials. Cancer Biol Ther 2010; 10:830-8.
17. Thirukkumaran C, Shi ZH, Spurrell J, Thirukkumaran P, Morris D. Breast cancer oncolysis by reovirus is mediated through upregulation of PUMA and NF-kB proteins of the apoptotic signalling pathway [abstract]. In: Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; 2007 Apr 14-18; Los angeles, CA: AACR;2007. Abstract nr 1929.
18. Pan D, Pan LZ, Hill R, Marcato P, Shmulevitz M, Vassilev LT, et al. Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-kappaB activation. Br J Cancer 2011;105:1012-22.
19. Connolly JL, Rodgers SE, Clarke P, Ballard DW, Kerr LD, Tyler KL, et al. Reovirus-induced apoptosis requires activation of transcription factor NF-kappaB. J Virol 2000;74:2981-9.
20. Clarke P, Meintzer SM, Gibson S, Widmann C, Garrington TP, Johnson GL, et al. Reovirus-induced apoptosis is mediated by TRAIL. J Virol 2000;74:8135- 9.
21. Clarke P, Meintzer SM, Spalding AC, Johnson GL, Tyler KL. Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus infection. Oncogene 2001;20:6910-9.
22. Kelly KR, Espitia C, Mahalingam D, Oyajobi BO, Coffey M, Giles FJ, et al. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene 2011;1-16.
23. Thirukkumaran CM, Luider JM, Stewart DA, Cheng T, Lupichuk SM, Nodwell MJ, et al. Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood 2003;102:377-87.
24. Cejkova S, Rocnova L, Potesil D, Smardova J, Novakova V, Chumchalova J, et al. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine. Eur J Haematol 2009;82:133-42.
25. Thirukkumaran CM, Luider JM, Stewart DA, Alain T, Russell JA, Auer IA, et al. Biological purging of breast cancer cell lines using a replica-tion- competent oncolytic virus in human stem cell autografts. Bone Marrow Transplant 2005;35:1055-64.
26. Nelson DL, Ledbetter SA, Corbo L, Victoria MF, Ramirez-Solis R, Webster TD, et al. Alu polymerase chain reaction: a method for rapid isolation of human-specific sequences from complex DNA sources. Proc Natl Acad Sci U S A 1989;86:6686- 90.
27. R: A Language and Environment for Statistical Computing [program]. 2.11 version. Vienna: R Foundation for Statistical Computing, 2011.
28. Liu YL, Yang PM, Shun CT, Wu MS, Weng JR, Chen CC. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy 2010;6:1057-65.
29. Levin B. Cell biology: autophagy and cancer. Nature 2007;446:745-7.
30. Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H, et al. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 2010;116:1460-8.
31. Liu KS, Liu H, Qi JH, Liu QY, Liu Z, Xia M, et al. SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells. Cancer Lett 2012; 318:180-8.
32. Acharya BR, Bhattacharyya S, Choudhury D, Chakrabarti G. The microtubule depolymerizing agent naphthazarin induces both apoptosis and autophagy in A549 lung cancer cells. Apoptosis 2011;16: 924-39.
33. Yang YF, Wu CC, Chen WP, Chen YL, Su MJ. Prazosin induces p53- mediated autophagic cell death in H9C2 cells. Naunyn Schmiedebergs Arch Pharmacol 2011;384:209-16.
34. Duan WJ, Li QS, Xia MY, Tashiro S, Onodera S, Ikejima T. Silibinin activated p53 and induced autophagic death in human fibrosarcoma HT1080 cells via reactive oxygen species-p38 and c-Jun N-terminal kinase pathways. Biol Pharm Bull 2011;34:47- 53.
35. Liu WT, Lin CH, Hsiao M, Gean PW. Minocycline inhibits the growth of glioma by inducing autophagy. Autophagy 2011;7:166-75.
36. Oh SH, Lim SC. Endoplasmic reticulum stress-mediated autophagy/ apoptosis induced by capsaicin (8-methyl-N-vanillyl-6-nonenamide) and dihydrocapsaicin is regulated by the extent of c-Jun NH2-terminal kinase/extracellular signal-regulated kinase activation in WI38 lung epithelial fibroblast cells. J Pharmacol Exp Ther 2009;329:112-22.
37. Appenzeller-Herzog C, Hall MN. Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling. Trends Cell Biol 2012; 1-9.
38. Qin L, Wang Z, Tao L, Wang Y. ER stress negatively regulates AKT/ TSC/mTOR pathway to enhance autophagy. Autophagy 2010;6: 239-47.